Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Q2 2020 Earnings Conference Call - Final Transcript
Aug 04, 2020 • 04:30 pm ET
Dean Schorno, C.P.A.
MidCap Financial. This facility provides the company with access to an additional $40 million, which is subject to the achievement of certain conditions.
With that, I'd like to turn the call back over to Raul. Raul?
Raul R. Rodriguez
Thank you, Dean. Moving on to slide 28, the COVID pandemic has clearly impacted our business. But it's also presented opportunities, for us to potentially contribute to a solution. And I cannot tell you how energized we are about this prospect. Let me summarize our efforts going forward, in each of the four key value drivers for the company.
We will continue to grow TAVALISSE in the U.S. ITP market. And we're excited about the use of TAVALISSE in earlier lines of therapy and the data that we have to support this position. Similarly, we look forward to supporting our partner Grifols, as they continue -- as they introduce physicians and patients, in Europe to TAVLESSE. We will work to complete the enrolment of our AIHA Phase 3 study with the re-initiation of screening and we look forward to enrolment increasing. We will expand our current lead in this area. And move forward to completion of that trial and filing an NDA. We will explore how to TAVALISSE could provide a -- potentially provide patients with COVID-related pneumonia, a much needed therapy. And we will continue to advance our RIP1 and IRAK1/IRAK14 programs, putting in place a partnership by year-end.
Before I turn the call over to you questions, I want to just make a quick note. I wanted to highlight an addition to our management team. Dave Santos will be joining Rigel as our Chief Commercial Officer. Dave brings over 30 years of experience in hematology/oncology areas, in various commercial leadership roles with numerous successful companies. I think he'll be a great addition to the team and we look forward to his contributions in helping us advance our commercial efforts. And, in that, I also want to thank Tarek for his contributions and look forward to those as well.
So, with that, I'd like to open up the call to your questions.